The firm provided updates alongside Q4 and full-year 2025 financial results, and reported $19.29 billion and $65.18 billion ...
The firm is hoping to make up for revenue lost to generic competition in coming years by growing adoption of treatments like ...
Researchers will use a blood-based biomarker developed in the VA Lung Precision Oncology Program to select best responders to the regimen.
The company is advancing TG4050 in head and neck cancer and possibly to other tumor types based on encouraging Phase I data.
The firm, which recently started a rolling BLA submission with the FDA for its Fabry disease gene therapy, will use the funds for general corporate expenses.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results